Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT01346072 Completed - Heart Failure Clinical Trials

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Start date: April 2011
Phase: Phase 4
Study type: Interventional

This study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin.

NCT ID: NCT01343810 Completed - Clinical trials for Cardiovascular Diseases

Stress Reduction Training to Improve Sleep Quality, Stress Physiology & Cardiovascular Disease (CVD) Risk Markers

Start date: September 2010
Phase: N/A
Study type: Interventional

The goal of this study is to better understand the potential value of reducing stress to ameliorate a cluster of biological and behavioral factors implicated in cardiovascular disease (CVD) risk. These factors include psychological distress, poor sleep quality, and exaggerated physiological responses to emotional stress. Results will be used to develop an innovative brief intervention to reduce risk for CVD by improving sleep quality, ameliorating psychological distress, and attenuating stress physiology.

NCT ID: NCT01343667 Completed - Clinical trials for Cardiovascular Diseases

GORE Flow Reversal System and GORE Embolic Filter Extension Study

FREEDOM
Start date: April 2011
Phase: N/A
Study type: Interventional

The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.

NCT ID: NCT01335737 Completed - Clinical trials for Cardiovascular Disease

Exercise and Inflammation

Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to test the hypothesis that aerobic exercise leads to attenuation of the inflammatory response to lipopolysaccharide (LPS) stimulation.

NCT ID: NCT01335022 Completed - Clinical trials for Cardiovascular Diseases

African American Community Health Project on Cardiovascular Disease

AACP-CVD
Start date: October 2010
Phase: Early Phase 1
Study type: Interventional

The investigators seek to demonstrate that interactive physician-led education through partnership with an African American church will improve awareness and knowledge of cardiovascular disease in the African American community and will result in objective improvement in major risk factors associated with cardiovascular disease (CVD).

NCT ID: NCT01334840 Completed - Clinical trials for Cardiovascular Diseases

Mechanism of Action of Vichy Catalan Water

Start date: November 2009
Phase: N/A
Study type: Interventional

Water consumption is essential to maintain hydration and good health. Sodium-bicarbonated mineral waters are reported to have beneficial digestive and hypocholesterolemic properties. The aim of this study was to investigate the effects of the consumption of a sodium-bicarbonated mineral water (BW) with or without a meal, compared to a low mineral content water as a control water (CW), on postprandial serum triacylglycerols (TAG), cholecystokinin (CCK), and gallbladder volume.

NCT ID: NCT01334268 Completed - Clinical trials for Coronary Artery Disease

RESOLUTE China RCT

R-China RCT
Start date: September 2011
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the in-stent late lumen loss (LLL) at 9 months, defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD, of the Resolute Zotarolimus-Eluting Coronary Stent System compared to Taxus Liberte Paclitaxel-Eluting Coronary Stent System in a real-world all-comer patient population requiring stent implantation.

NCT ID: NCT01333644 Completed - Inflammation Clinical Trials

The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk

Start date: April 2010
Phase: N/A
Study type: Observational

It is the central hypothesis of the investigators study that HIV disease is a pro-inflammatory condition, and that years of inflammation result in premature "aging' of the immune system ("immunosenescence"). Just as these changes are thought be causally associated with heart disease in the very old,the investigators postulate that these changes will be associated with early heart disease in the untreated and perhaps treated HIV disease. To address this hypothesis, the investigators will measure immunosenescence in a large cohort of patients who span the entire disease process.

NCT ID: NCT01333241 Completed - Clinical trials for Cardiovascular Diseases

Healthy Lifestyle Behavior Intervention for Latino Women

Start date: August 2009
Phase: N/A
Study type: Interventional

The overall goal of this randomized controlled trial is to evaluate the effects of a community-based lifestyle behavior intervention (LSBI) that is designed to improve dietary habits and physical activity (PA), and reduce weight of Latino women who are predominantly Spanish-speaking immigrants. It is hypothesized that middle-aged overweight/obese Latinas participating in a LSBI conducted by lay health advisors will demonstrate improved dietary habits, increased physical activity and a decrease in BMI compared to those in a control condition, Women in the LSBI also are expected to demonstrate improvements in selected physiologic outcomes (waist circumference, blood pressure [BP], measures of cholesterol and blood sugar).

NCT ID: NCT01331317 Completed - Clinical trials for Cardiovascular Disease

Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The primary objective is to assess the impact of three months of treatment with an active vitamin D analogue on a risk marker for excess overall mortality and cardiovascular morbidity/mortality in Type 1 diabetic patients with diabetic kidney disease. The hypothesis is that active vitamin D analogue treatment reduces the risk of cardiovascular morbidity and mortality in patients with type 1 diabetic kidney disease.